

Client: Example Client ABC123
123 Test Drive
Salt Lake City, UT 84108
UNITED STATES

Physician: Doctor, Example

Patient: Patient, Example

DOB: 7/19/1936
Sex: Female
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Collection Date: 01/01/2017 12:34

Leukemia/Lymphoma Phenotyping Evaluation by Flow Cytometry

ARUP test code 3001780

Leuk/Lymph Phenotype, Impression

see note

SPECIMEN: Peripheral Blood

IMPRESSION:

Atypical myeloid blasts identified accounting for 92% of the viable leukocytes, favor Acute Myeloid Leukemia. See comment

COMMENT:

Correlation with morphologic and cytogenetic findings will be required to make a definitive diagnosis. The high blast fraction by flow cytometry is concerning for AML, however classification will require morphologic evaluation of the blast fraction and cytogenetic and molecular correlation, along with bone marrow evaluation that includes cytogenetic studies. Please also correlate the results from this study with pending cytogenetic and other ancillary testing.

ANALYSIS:

Differential:

Lymphocytes: 4%
Monocytes: 1%
Granulocytes: 3%
Atypical cells: 92%

Atypical cells: Myeloid blasts

Immunophenotype:

* Positive: partial CD4, CD7, CD13, CD33, partial CD34, variable CD38, dim CD45, CD117, CD123, HLA-DR, MPO
* Negative: CD2, CD5, CD10, CD11b, CD14 (MO2), CD15, CD19, CD20, CD41, CD42b, CD61, CD64, CD71, cCD79a, CD235a, Cyto CD3, TDT, CD56
* Phenotypic abnormalities: CD7 positive

Lymphocytes:

B-cells: 27%
T-cells: 57%
NK-cells: 11%

Kappa: Lambda Ratio: 1.5, polytypic

CD4:CD8 Ratio: normal at 1.7

NK-cells: No abnormality

Monocytes: No abnormality, left shifted with partial CD14

Myeloid cells: No abnormality, left shifted with partial CD10, partial CD11b, and partial CD16

Viability: 95%

Disclaimers: none

Markers run: Kappa, Lambda, CD19, CD5, CD23, CD10, CD38, CD200, CD20, CD45, CD57, CD7, CD4, CD2, CD56, CD8, CD3, CD16, CD14,

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

CD33, CD13, CD117, CD11b, CD34, CD64, HLA-DR, CD123, CD71, CD15, TDT, MPO, cCD79a, Cyto CD3, CD235a, CD41, CD61, CD42b, CD36

These results have been reviewed and approved by [REDACTED]

INTERPRETIVE INFORMATION: Leuk/Lymph Phenotyping, Flow Cytometry

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. This test was performed in a CLIA certified laboratory and is intended for clinical purposes.

Leuk/Lymph Phenotype, Source	Blood
Number Of Markers	38 markers

VERIFIED/REPORTED DATES				
Procedure	Accession	Collected	Received	Verified/Reported
Leuk/Lymph Phenotype, Impression	22-001-400205	1/1/2022 5:42:00 AM	1/2/2022 5:44:55 PM	1/3/2022 5:14:00 PM
Leuk/Lymph Phenotype, Source	22-001-400205	1/1/2022 5:42:00 AM	1/2/2022 5:44:55 PM	1/3/2022 5:14:00 PM
Number Of Markers	22-001-400205	1/1/2022 5:42:00 AM	1/2/2022 5:44:55 PM	1/3/2022 5:14:00 PM

END OF CHART

H=High, L=Low, *=Abnormal, C=Critical

Unless otherwise indicated, testing performed at:

ARUP LABORATORIES | 800-522-2787 | aruplab.com
500 Chipeta Way, Salt Lake City, UT 84108-1221
Jonathan R. Genzen, MD, PhD, Laboratory Director

Patient: Patient, Example
ARUP Accession: 22-001-400205
Patient Identifiers: 01234567890ABCD, 012345
Visit Number (FIN): 01234567890ABCD
Page 2 of 2 | Printed: 8/4/2022 7:40:38 AM